Article révisé par les pairs
Titre:
  • 18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO.
Auteur:Gebhart, Géraldine; Gamez, Cristina; Holmes, Eileen; Robles Barba, Javier; Garcia, Camilo; Cortés, Montserrat; de Azambuja, Evandro; Fauria, Karine; van Dooren, Veerle; Aktan, Gursel; Coccia-Portugal, Maria; Kim, Sung-Bae; Vuylsteke, Peter; Cure, Hervé; Eidtmann, Holger; Baselga, José; Piccart-Gebhart, Martine; Flamen, Patrick; Di Cosimo, Serena
Informations sur la publication:The Journal of nuclear medicine, 54, 11, page (1862-1868)
Statut de publication:Publié, 2013-11
Sujet CREF:Sciences bio-médicales et agricoles
Mots-clés:18F-FDG-PET/CT
anti-HER2 drugs
early response assessment
MeSH keywords:Antibodies, Monoclonal, Humanized -- administration & dosage -- therapeutic use
Antineoplastic Combined Chemotherapy Protocols
Breast Neoplasms -- diagnosis -- drug therapy -- metabolism
Female
Fluorodeoxyglucose F18 -- diagnostic use
Humans
Neoadjuvant Therapy
Positron-Emission Tomography
Quinazolines -- administration & dosage -- therapeutic use
Receptor, ErbB-2 -- metabolism
Time Factors
Tomography, X-Ray Computed
Treatment Outcome
Tumor Markers, Biological -- metabolism
Note générale:SCOPUS: ar.j
Langue:Anglais
Identificateurs:urn:issn:0161-5505
info:doi/10.2967/jnumed.112.119271
info:pii/jnumed.112.119271
info:scp/84890308316
info:pmid/24092940

Documents en relation

DI-fusion